Chordate’s CEO Anders Weilandt is interviewed by the news service Biostock about the newly released interim report for July-September 2022 and the planned rights issue. Anders Weilandt on the quarter:
” As the most exciting quarter so far in the company’s history – is probably the short answer. First getting the results of the subgroup, and then the analysis of the entire study material, is a confirmation of so many years of hard work and beats most of what the company has experienced. The entire Chordate project has now been “de-risked” down to a completely new and much more comfortable level.”